Evaluation of Agaricus blazei in vivo for antigenotoxic, anticarcinogenic, phagocytic and immunomodulatory activities

Centro de Estudos em Nutrição e Genética Toxicológica-CENUGEN, Departamento de Nutrição, Centro Universitário Filadélfia, Londrina-PR, Brazil.
Regulatory Toxicology and Pharmacology (Impact Factor: 2.03). 02/2011; 59(3):412-22. DOI: 10.1016/j.yrtph.2011.01.004
Source: PubMed


The development of various types of cancer results from the interaction among endogenous, environmental and hormonal factors, where the most notable of these factors is diet. The aim of the present study was to determine the antigenotoxic, anticarcinogenic, phagocytic and immunomodulatory activities of Agaricus blazei. The test antigenotoxicity (Comet Assay) and anticarcinogenic (Test of Aberrant Crypt Foci) assess changes in DNA and/or intestinal mucosa that correlate to cancer development. Tests of phagocytosis in the spleen and differential count in blood cells allow the inference of modulation of the immune system as well as to propose a way of eliminating cells with DNA damage. Supplementation with the mushroom was carried out under pre-treatment, simultaneous treatment, post-treatment and pre-treatment+continuous conditions. Statistical analysis demonstrated that the mushroom did not have genotoxic activity but showed antigenotoxic activity. Supplementation caused an increase in the number of monocytes and in phagocytic activity, suggesting that supplementation increases a proliferation of monocytes, consequently increasing phagocytic capacity especially in the groups pre-treatment, simultaneous and pre-treatment+continuous. The data suggest that A. blazei could act as a functional food capable of promoting immunomodulation which can account for the destruction of cells with DNA alterations that correlate with the development of cancer, since this mushroom was demonstrated to have a preventive effect against pre-neoplastic colorectal lesions evaluated by the aberrant crypt foci assay. According to these results and the literature, it is believed that supplementation with A. blazei can be an efficient method for the prevention of cancer as well as possibly being an important coadjuvant treatment in chemotherapy.

Download full-text


Available from: Mário Sérgio Mantovani, Oct 14, 2014
  • Source
    • "It is noteworthy that the spleen is a lymphoid organ related to hemocatheresis, storage and release of cells into the bloodstream (Ramadan et al., 2012). Therefore, the results of the phagocytic activity, when associated with antimutagenicity data suggest the phagocytosis of micronucleated cells by the spleen (Ishii et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Inflammatory and genetic alterations are related to the development of chronic diseases such as cancer. Schinus terebinthifolius Raddi, Anacardiaceae, is used in folk medicine to treat in- flammation, wounds and tumors. This study evaluated the anti-inflammatory, immunomod- ulatory, chemopreventive, and wound healing potentials of the methanolic extract from the leaves of Schinus terebinthifolius. The chemical composition of the extract was characterized using preliminary analytical LC methods. The results showed that the anti-inflammatory ac- tivity of the methanolic extract was similar to that of dexamethasone for edema reduction. Also, it inhibited the leukocyte migration into the air pouch and decreased plasma extrava- sation. In addition, the methanolic extract showed a healing action similar to that observed with collagenase. The methanolic extract is not genotoxic nor mutagenic, and in contrast it has chemopreventive activity, which elicits a high percentage of damage reduction by comet and micronucleus assay, preferably by bioantimutagenic action. The methanolic extract in- duced apoptosis and enhanced splenic phagocytosis in animals treated with cyclophospha- mide. The methanolic extract contents, resolved by LC, include phenolic acid and flavonoids. Our results suggest a therapeutic potential for the methanolic extract.
    Revista Brasileira de Farmacognosia 10/2014; 13(5). DOI:10.1016/j.bjp.2014.08.004 · 0.83 Impact Factor
  • Source
    • "We selected 3 protocols from those proposed in the literature: pre-treatment, simultaneous, and post-treatment. An alternative protocol of pre + continuous proposed by Ishii et al. (2011) was also used. This simple treatment protocol indicates desmutagenic or bioantimutagenic activity; the pretreatment protocol largely indicates bioantimutagenic activity, and the post-treatment protocol exclusively shows bioantimutagenic activity. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Previous studies in rodents treated with the pro-carcinogen 1,2-dimethylhydrazine suggested that the consumption of wheat bran protected against DNA damage in the colon and rectum. Based on this information, we evaluated wheat bran as a functional food in the prevention and treatment of colon cancer. We used the aberrant crypt focus assay to evaluate the anticarcinogenic potential of wheat bran (Triticum aestivum variety CD-104), the comet assay to evaluate its antigenotoxicity potential, and the micronucleus assay to evaluate its antimutagenic potential. The wheat bran gave good antimutagenic and anticarcinogenic responses; the DNA damage decreased from 90.30 to 26.37% and from 63.35 to 28.73%, respectively. However, the wheat bran did not significantly reduce genotoxicity. Further tests will be necessary, including tests in human beings, before this functional food can be recommended as an adjunct in the prevention and treatment of colon cancer.
    Genetics and molecular research: GMR 06/2013; 12(2):1646-59. DOI:10.4238/2013.May.14.5 · 0.78 Impact Factor
  • Source
    • "2008).Aα-(1→4)-Glucan-β-(1→6)-glucan-proteincom- plexisolatedfromA.subrufescensshowedtumor growth-inhibitoryeffectthroughthehost-mediatedmechanisms,andseveralclinicaltrialshaveshownitspharmacolog- icalbenefitsoncancertreatmentandimmunostimulation (Gonzagaetal.2009;Ishiietal.2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Fungal Diversity, 55 (1), 1-35 (2012). Medicinal mushrooms have been valued as natural sources of bioactive compounds since times immemorial and have been recognized as potential immunomodulating and anti-cancer agents. Their consumption has consistently been shown to have beneficial effects on human health. Cancer is a generic term for several types of diseases that can be chronic and are responsible for a large number of deaths worldwide. Although there has been considerable progress in modern cancer therapy research, difficulties in understanding the molecular behavior of various types of cancers and the numerous side effects experienced by patients from treatments means that this whole subject area is still problematic. Thus, biological immunotherapy using natural bioactive compounds as supportive treatments in conventional cancer therapies has become in vogue. Bioactive metabolites isolated from medicinal mushrooms have shown potential successes in cancer treatment as biological immunotherapeutic agents that stimulate the immune system against cancer cells. They also act as an effective source of anti-cancer agents, capable of interfering with cellular signal transduction pathways linked to cancer development and progression. In this review we compile available data on the characteristics of medicinal mushrooms that appear to be particularly effective as biological immunotherapeutic agents. Major consideration is given to biological constituents and the putative mechanisms of action by which bioactive compounds act on the human body. Consideration is also given to the benefits that have been claimed for the use of mushrooms in treating cancer and the future prospects of using medicinal mushrooms as potent supportive candidate bioagents for treatment of cancers is discussed.
    Fungal diversity 07/2012; 55(1):1-35. DOI:10.1007/s13225-012-0151-3 · 6.22 Impact Factor
Show more